U.S. markets closed

Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
94.60+2.67 (+2.90%)
At close: 4:00PM EDT

Neurocrine Biosciences, Inc.

12780 El Camino Real
San Diego, CA 92130
United States
858 617 7600
http://www.neurocrine.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees865

Key Executives

NameTitlePayExercisedYear Born
Dr. Kevin C. GormanCEO & Director1.38MN/A1958
Mr. Matthew C. AbernethyChief Financial Officer781.04k549.13k1980
Mr. Kyle W. GanoChief Bus. Devel. and Strategy Officer711.72kN/A1973
Mr. Eric S. BenevichChief Commercial Officer748.83k1.25M1965
Ms. Eiry Wyn RobertsChief Medical Officer847.94k260.95k1964
Dr. Dimitri E. GrigoriadisChief Research OfficerN/AN/A1958
Jane SorensenHead of Investor RelationsN/AN/AN/A
Mr. Darin M. LippoldtChief Legal Officer & Corp. Sec.N/AN/A1966
Ms. Julie S. CookeChief HR OfficerN/AN/A1966
Mr. Malcolm C. Lloyd-SmithChief Regulatory OfficerN/AN/A1956
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Corporate Governance

Neurocrine Biosciences, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 5. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 5; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.